期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

抗蛋白酶降解肽类药物的结构修饰研究进展 被引量：2

下载PDF
导出
摘要 多肽类药物的蛋白酶降解稳定性是决定该药物是否长效的重要因素。本文综述了近年来用以提高多肽药物蛋白酶降解稳定性的主要策略,尤其对特定位置如N端、C端及氨基酸侧链等的化学结构修饰进行了分类和概述,探讨了这些修饰方法对发展多肽药物的贡献及不足。
作者 付慧君 周宁 周英 刘克良
机构地区 贵州大学生命科学学院 军事医学科学院毒物药物研究所
出处 《国外医学（药学分册）》 2006年第4期269-271,299,共4页 Foreign Medical Sciences(Section of Pharmarcy)
关键词 肽类药物 蛋白酶 降解 结构修饰
分类号 R914 [医药卫生—药物化学]
  • 相关文献

参考文献21

  • 1王萍,陈钧.酶抑制剂在蛋白质和肽类药物口服制剂中的应用[J].中国医药工业杂志,2005,36(8):510-514. 被引量：2
  • 2Reddy KR.Controlled-release,pegylation,liposomal formulations:new mechanisms in the delivery of injectable drugs[J].Ann Pharmacother,2000,34(7/8):915-923.
  • 3Shechter Y,Tsubery H,Mironchik M,et al.Reversible PEGylation of peptide YY3-36 prolongs its inhibition of food intake in mice[J].FEBS Lett,2005,579(11):2439-2444.
  • 4Francesco MV,Gianfranco P.PEGylation,successful approach to drug delivery[J].Drug Discov Today,2005,10(22):1451-1458.
  • 5Witt KA,Huber JD,Eqleton RD,et al.Pharmacodynamic and pharmacokinetic characterization of poly(ethylene glycol) conjugation to Met-enkephalin analog[D-Pen2,D-Pen5]enkephalin(DPDPE)[J].J Phamacol Exp Ther,2001,298(1-3):848-856.
  • 6Maeda H.SMANCS and polymer-conjugated macromolecular drugs:advantages in cancer chemotherapy[J].Adv Drug Deliv Rev,2001,46(2):169-185.
  • 7李炜,章承继,仇缀百.阿片类前体药物的研究进展[J].中国药物化学杂志,2004,14(1):51-55. 被引量：1
  • 8Witt KA,Gillespie TJ,Huber JD,et al.Peptide drug modification to enhance bioavailability and blood-brain barrier permeability[J].Peptides,2001,22(12):2329-2343.
  • 9Bak A,Fich M,Larsen BD,et al.N-terminal 4-imidazolidinone prodrugs of leu-enkephalin:synthesis,chemical and enzymatic stability studies[J].Eur J Pharm Sci,1999,7(4):317-323.
  • 10Bundgaard H,Rusmussen GJ.Prodrugs of peptides 9.Bioreversible N-alpha-hydroxyalkylation of the peptide bond to effect protection against carboxypeptidase or other proteolytic enzymes[J].Pharm Res,1991,8(3):313-322.

二级参考文献30

  • 1胡幼圃 王志中 何善台.那布扶林镇痛剂长效前体药物及其制备方法[P].中国专利:1049577.2000-01-22.
  • 2Tengamnuay P, Sahamethopat A, Sailasuta A, et al. Chitosan as nasal absorption enhancers of peptides: Comparison beween free amine chitosans and soluble salts [J]. Int J Pharm, 2000,197 (1-2): 53-67.
  • 3Al-Achi A, Greenwood R. Buccal administration of human insulin in streptozocin -diabetic rats [J]. Res Commun Chem Pathol Pharmacol, 1993, 82 (3): 297-306.
  • 4Laube BL, Benedict GW, Dobs AS. The lung as an alternative route of delivery for insulin in controlling postprandial glucose levels in patients with diabetes [J]. Chest, 1998, 114 (6):1734-1739.
  • 5Suzuki A, Morishita M, Kajita M, et al. Enhanced colonic and rectal absorption of insulin using a multiple emulsion containing eicosapentaenoic acid and docosahexaenoic acid [J]. J Pharm Sci, 1998, 87 (10): 1196-1202.
  • 6Fang Q, Wu C, Li L, et al. Some features of intestinal absorption of intact fibrinolytic enzyme Ⅲ-1 from Lumbricus rubellus[J]. Biochim BiophysActa, 2001, 1526 (3): 286-292.
  • 7Miyata K, Hirai S, Yashiki T, et al. Intestinal absorption of serratia protease [J]. J Appl Biochem, 1980, 2 (2): 111-116.
  • 8Lennernas H. Human intestinal permeability [J].J Pharm Sci,1998, 87 (4): 403-410.
  • 9Fujii S, Yokoyama T, Ikegaya K, et al. Promoting effect of the new chymotrypsin inhibitor FK-448 on the intestinal absorption of insulin in rats and dogs [J]. J Pharm Pharmacol,1985, 37(8): 545-549.
  • 10Okagawa T, Fujita T, Murakami M, et al. Susceptibility of ebiratide to proteolysis in rat intestinal fluid and homogenates and its protection by various protease inhibitors [J]. Life Sci,1994, 55 (9): 677-683.

共引文献1

同被引文献31

  • 1王宇新,周晓巍,党颖,黄培堂.提高蛋白质和多肽类药物代谢稳定性的研究进展[J].生物技术通讯,2005,16(6):665-667. 被引量：6
  • 2戚楠,马清钧.长效重组蛋白药物的研究进展[J].中国生物工程杂志,2006,26(2):79-82. 被引量：22
  • 3张法,刘刚.糖肽的固相合成[J].化学进展,2006,18(5):579-600. 被引量：3
  • 4Subramanian M G, Fiscella M, Lamouse-Smith A, et al. Albinterferoncα-2b :a genetic fusion protein for the treatment of chronic hepatitis C. Nat Biotechnol, 2007,25 ( 12 ) : 1411 - 1419.
  • 5Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discovery Today, 2005, 10 (21) :1451 - 1458.
  • 6Stigsnaes P, Frokjaer S, Bjerregaard S, et al. Characterisation and physical stability of PEGylated glucagon. Int J Pharm, 2007, 330(1-2) :89 -98.
  • 7Duttaroy A, Kanakaraj P, Osborn L B, et al. Development of a long-acting insulin analog using albumin fusion technology. Diabetes, 2005, 54(1 ):251 -258.
  • 8Chen J Q, Bai G, Cao Y, et al. One-step purification of a fusion protein of glueagons-like peptide-1 and human serum albumin expressed in Pichia pastoris by an immunomagnetic separation technique. Biosei Biotechnol Biochem, 2007, 71 ( 11 ) :2655 - 2662.
  • 9Miiller D, Karle A, Meissburger B, et al. Improved pharmacokinetics of recombinant bispecific antibody molecules by fusion to human serum albumin. J Biol Chem, 2007, 282 ( 17 ) : 12650 - 12660.
  • 10Chan Y P, Meyrueix R, Kravtzoff R, et al. Review on Medusa (R) : a polymer-based sustained release technology for protein and peptide drugs. Expert Opin Drug Deliv, 2007, 4(4) :441 -451.

引证文献2

二级引证文献15

国外医学（药学分册）
2006年 第4期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部